Who Paid My Doc
Dan Reinstein
Optometrist, Corneal and Contact Management London Medical Doctor
NPI 1770900995 CMS profile 1068746
138 Harley Street, London W1G 7
General payments
$2,636,510
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Dan Reinstein of London is reported in the CMS Open Payments database as having received $2,636,510 across 191 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Optometrist, Corneal and Contact Management profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $203 | 2 | |
| 2024 | General | $341,243 | 14 | |
| 2023 | General | $414,289 | 25 | |
| 2022 | General | $389,266 | 34 | |
| 2021 | General | $341,183 | 28 | |
| 2020 | General | $742,940 | 61 | |
| 2019 | General | $407,386 | 27 |
Beside peers
- Dan Reinstein
- Optometrist, Corneal and Contact Management median
- Middle half of Optometrist, Corneal and Contact Management
- National median
In program year 2025, general payments to Dan Reinstein were reported at $203. Among 618 Optometrist, Corneal and Contact Management profiles paid that year, the median was $227 and the middle half received between $95 and $604.
Show as a table
| Year | Dan Reinstein | Optometrist, Corneal and Contact Management median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $407,386 | $203 | $84–$530 | $163 |
| 2020 | $742,940 | $88 | $35–$234 | $114 |
| 2021 | $341,183 | $143 | $54–$353 | $132 |
| 2022 | $389,266 | $167 | $65–$422 | $149 |
| 2023 | $414,289 | $195 | $76–$549 | $160 |
| 2024 | $341,243 | $202 | $85–$523 | $164 |
| 2025 | $203 | $227 | $95–$604 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
191 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.